For help on how to get the results you want, see our search tips.
586 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Orphan designations Remove Orphan designations filter
Categories
Human Remove Human filter
Orphan designation status
Withdrawn Remove Withdrawn filter
-
List item
Orphan designation: Recombinant human alpha-1-microglobulin for: Treatment of pre-eclampsia (updated)
Date of first decision: 04/07/2014, Withdrawn, Last updated: 11/05/2021 -
List item
Orphan designation: tripotassium citrate monohydrate, Potassium hydrogen carbonate for: Treatment of distal renal tubular acidosis (updated)
Date of first decision: 20/06/2017, Withdrawn, Last updated: 03/05/2021 -
List item
Orphan designation: Codon-optimised human ornithine transcarbamylase mRNA complexed with lipid-based nanoparticles for: Treatment of ornithine transcarbamylase deficiency (updated)
Date of first decision: 27/06/2018, Withdrawn, Last updated: 28/04/2021 -
List item
Orphan designation: Ixazomib for: Treatment of systemic light chain amyloidosis
Date of first decision: 08/11/2012, Withdrawn, Last updated: 09/04/2021 -
List item
Orphan designation: 2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-alpha]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile (ziritaxestat) for: Treatment of idiopathic pulmonary fibrosis
Date of first decision: 29/08/2016, Withdrawn, Last updated: 09/04/2021 -
List item
Orphan designation: Chimeric monoclonal antibody against claudin 6 for: Treatment of ovarian cancer
Date of first decision: 24/01/2013, Withdrawn, Last updated: 08/04/2021 -
List item
Orphan designation: Recombinant human glutamate oxaloacetate transaminase 1 for: Treatment of glioma
Date of first decision: 12/02/2015, Withdrawn, Last updated: 07/04/2021 -
List item
Orphan designation: romilkimab for: Treatment of systemic sclerosis
Date of first decision: 09/01/2020, Withdrawn, Last updated: 06/04/2021 -
List item
Orphan designation: ziritaxestat for: Treatment of systemic sclerosis
Date of first decision: 09/01/2020, Withdrawn, Last updated: 06/04/2021 -
List item
Orphan designation: Terguride for: Treatment of systemic sclerosis
Date of first decision: 24/01/2013, Withdrawn, Last updated: 22/03/2021 -
List item
Orphan designation: milciclib maleate for: Treatment of malignant thymoma
Date of first decision: 08/11/2012, Withdrawn, Last updated: 22/03/2021 -
List item
Orphan designation: Allogeneic umbilical cord blood CD34+ cells cultured ex vivo with Notch ligand Delta1 (dilanubicel) for: Treatment in haematopoietic stem cell transplantation
Date of first decision: 17/01/2018, Withdrawn, Last updated: 22/03/2021 -
List item
Orphan designation: Levosimendan for: Treatment of amyotrophic lateral sclerosis
Date of first decision: 22/02/2018, Withdrawn, Last updated: 19/03/2021 -
List item
Orphan designation: Humanised single-chain monoclonal antibody against CD37 (otlertuzumab) for: Treatment chronic lymphocytic leukaemia
Date of first decision: 06/12/2012, Withdrawn, Last updated: 19/03/2021 -
List item
Orphan designation: Adeno-associated viral vector serotype 8 containing the human UGT1A1 gene (volrubigene ralaparvovec) for: Treatment of Crigler-Najjar syndrome
Date of first decision: 22/08/2014, Withdrawn, Last updated: 19/03/2021 -
List item
Orphan designation: Nimorazole maleate for: Treatment of squamous-cell carcinoma of the head and neck in patients undergoing radiotherapy
Date of first decision: 09/02/2012, Withdrawn, Last updated: 19/03/2021 -
List item
Orphan designation: Three chimeric human/murine monoclonal antibodies against the Ebola (Zaire) surface glycoprotein (porgaviximab) for: Treatment for Ebola virus disease
Date of first decision: 09/10/2015, Withdrawn, Last updated: 19/03/2021 -
List item
Orphan designation: 5-(Ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole (ezutromid) for: Treatment of Duchenne muscular dystrophy
Date of first decision: 04/12/2008, Withdrawn, Last updated: 10/02/2021 -
List item
Orphan designation: Human monoclonal antibody against Pseudomonas aeruginosa IATS-O1 for: Treatment of pneumonia caused by serotype O1 Pseudomonas aeruginosa
Date of first decision: 28/01/2010, Withdrawn, Last updated: 03/02/2021 -
List item
Orphan designation: RNA, [P-deoxy-P-(dimethylamino)] (2',3'-dideoxy-2',3'-imino-2',3'-seco) (2'a→5') (C-m5U-m5U-A-C-A-G-G-C-m5U-C-C-A-A-m5U-A-G-m5U-G-G-m5U-C-A-G-m5U), 5' [P-[4-[[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]carbonyl]-1-piperazinyl]-N,N-dimethylaminophosphonamidate], 3'-[2'a-[N2-acetyl-L-arginyl-6-aminohexanoyl-L-arginyl-L-arginyl-β-alanyl-L-arginyl-L-arginyl-6-aminohexanoyl-L-arginyl-L-arginyl-β-alanyl-L-arginyl-6-aminohexanoyl-β-alanyl], octahydrochloride for: Treatment of Duchenne muscular dystrophy
Date of first decision: 02/02/2010, Withdrawn, Last updated: 03/02/2021 -
List item
Orphan designation: Sodium thiosulfate for: Treatment of calciphylaxis
Date of first decision: 23/02/2011, Withdrawn, Last updated: 03/02/2021 -
List item
Orphan designation: Adeno-associated viral vector serotype 8 containing the human UGT1A1 gene (volrubigene ralaparvovec) for: Treatment of Crigler-Najjar syndrome
Date of first decision: 18/11/2016, Withdrawn, Last updated: 03/02/2021 -
List item
Orphan designation: Heparin-activated recombinant human fibroblast growth factor 1 (on a biodegradable device made from alpha-calcium sulfate hemihydrate) for: Treatment of traumatic spinal cord injury
Date of first decision: 27/07/2010, Withdrawn, Last updated: 03/02/2021 -
List item
Orphan designation: (1S,3S)-3-amino-4-(difluoromethylene) cyclopentanecarboxylic acid hydrochloride for: Treatment of West syndrome
Date of first decision: 09/02/2012, Withdrawn, Last updated: 03/02/2021 -
List item
Orphan designation: Rovalpituzumab tesirine for: Treatment of small cell lung cancer
Date of first decision: 30/05/2016, Withdrawn, Last updated: 03/02/2021